This company has shut down. OccuRx is no longer operating — its last tracked round was a Series B in 2022.
Explore the Startup GraveyardOccuRx is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies.
OccuRx has raised $14.5M in total funding. The most recent round was Series B. The last funding was announced in September 2022.
OccuRx's investors include Brandon Capital, Uniseed, Stoic VC, Brandon BioCatalyst, Medical Research Commercialisation Fund (MRCF).
OccuRx is headquartered in Melbourne, Australia.
OccuRx is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies.
OccuRx is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OccuRx — Funding & Investors." VCBacked, September 6, 2022, https://www.vcbacked.co/company/occurx. Accessed August 15, 2026.
VCBacked. (2022). OccuRx — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/occurx
{{cite web |title=OccuRx — Funding & Investors |url=https://www.vcbacked.co/company/occurx |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated